275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

Mueller, Volkmar; Paplomata, Elisavet; Hamilton, Erika; Zelnak, Amelia; Fehrenbacher, Louis; Jakobsen, Erik; Curtit, Elsa; Boyle, F.; Brix, Eva; Brenner, Andrew; Ferrario, Cristiano; Muñoz-Mateu, Montserrat; Arkenau, Tobias; Gelmon, Karen A.; Cameron, David; Curigliano, Giuseppe; DeBusk, Kendra; Ramos, Jorge; An, Xuebei; Wardley, Andrew M

doi:10.1016/j.annonc.2020.08.377

Cited by 6 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a sub-study of health-related QoL in the HER2CLIMB trial, no significant differences were seen between the treatment arms although QoL was maintained for longer in patients randomised to tucatinib. 86 While tucatinib has proven its efficacy and tolerability, further information is required on its cost-effectiveness for the global population.…”

Section: Dovepressmentioning

confidence: 99%

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib

Ulrich

Okines

2021

BCTT

View full text Add to dashboard Cite

The management of HER2 positive breast cancer has been transformed by the development of targeted therapies. Dual blockade with the monoclonal antibodies, trastuzumab and pertuzumab, added to first-line taxane chemotherapy and second-line therapy with the antibody-drug conjugate, T-DM1, are internationally agreed standards of care for advanced HER2 positive breast cancer, where available. However, until recently, options for patients for third-line therapy and beyond were of modest efficacy or limited by toxicity. In 2019, the results of trials of two exciting new agents for this space were presented. A third-generation HER2 tyrosine kinase inhibitor, tucatinib, combines the efficacy of the second-generation drug, neratinib, with a more manageable toxicity profile and has become a new standard of care after T-DM1, in combination with capecitabine and trastuzumab. The antibody-drug conjugate, trastuzumab deruxtecan, demonstrated remarkable efficacy in heavily pre-treated patients and received accelerated approval in the United States, whilst confirmatory Phase 3 trials are completed. This review will discuss the available data for the post-T-DM1 setting, focusing on tyrosine kinase inhibitors including tucatinib.

show abstract

Section: Dovepressmentioning

confidence: 99%

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib

Ulrich

Okines

2021

BCTT

View full text Add to dashboard Cite

show abstract

“…For patients with HER2-positive breast cancer who have already been treated with all standard options, further treatment options with tucatinib and trastuzumab deruxtecan will most likely be available in the future (after a pending authorisation in Europe) 37 , 50 . Quality-of-life data have recently been published for the randomised HER2CLIMB study 51 . In this analysis, in which almost half of all patients had brain metastases, the addition of tucatinib to trastuzumab and chemotherapy did not result in any difference in quality of life 51 despite a more unfavourable side-effect profile 50 .…”

Section: Treatment Of Patients With Metastatic Breast Cancermentioning

confidence: 99%

“…Quality-of-life data have recently been published for the randomised HER2CLIMB study 51 . In this analysis, in which almost half of all patients had brain metastases, the addition of tucatinib to trastuzumab and chemotherapy did not result in any difference in quality of life 51 despite a more unfavourable side-effect profile 50 . It is worth noting that significant benefits in progression-free survival and overall survival had already been reported for tucatinib when comparing the randomisation arms 50 .…”

Section: Treatment Of Patients With Metastatic Breast Cancermentioning

confidence: 99%

“…Für Patientinnen mit HER2-positivem Mammakarzinom, die bereits mit allen Standardoptionen therapiert worden waren, werden in Zukunft aller Wahrscheinlichkeit nach mit Tucatinib und Trastuzumab-Deruxtecan (nach einer noch ausstehenden Zulassung in Europa) weitere Therapieoptionen verfügbar sein 37 , 50 . Im Rahmen der randomisierten HER2CLIMB-Studie sind nun kürzlich Lebensqualitätsdaten veröffentlicht worden 51 . In dieser Analyse, bei der fast die Hälfte aller Patientinnen Hirnmetastasen hatte, zeigte sich durch die Hinzunahme von Tucatinib zu Trastuzumab und Chemotherapie trotz eines ungünstigeren Nebenwirkungsprofils 50 kein Unterschied in der Lebensqualität 51 .…”

Section: Lebensqualität Im Fokusunclassified

“…Im Rahmen der randomisierten HER2CLIMB-Studie sind nun kürzlich Lebensqualitätsdaten veröffentlicht worden 51 . In dieser Analyse, bei der fast die Hälfte aller Patientinnen Hirnmetastasen hatte, zeigte sich durch die Hinzunahme von Tucatinib zu Trastuzumab und Chemotherapie trotz eines ungünstigeren Nebenwirkungsprofils 50 kein Unterschied in der Lebensqualität 51 . Zu erwähnen ist, dass beim Vergleich der Randomisationsarme bereits signifikante Vorteile für Tucatinib in Bezug auf das progressionsfreie Überleben und das Gesamtüberleben berichtet worden waren 50 .…”

Section: Lebensqualität Im Fokusunclassified

See 2 more Smart Citations

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Lux

Schneeweiß

Hartkopf

et al. 2021

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.

show abstract

Update Mammakarzinom 2020 Teil 5 – Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation

Lux

Schneeweiß

Hartkopf

et al. 2021

Senologie - Zeitschrift für Mammadiagnostik und -therapie

View full text Add to dashboard Cite

ZusammenfassungBei neuen Therapieansätzen des Mammakarzinoms sind insbesondere bei Patientinnen mit HER2-positivem und HER2-negativem/hormonrezeptorpositivem (HR+) Mammakarzinom in den letzten Jahren deutliche Fortschritte gesehen worden. Bei HER2-positiven Tumoren müssen in dem Zusammenhang Pertuzumab, T‑DM1, Neratinib und bald auch Tucatinib und Trastuzumab-Deruxtecan (beide in Europa noch nicht zugelassen) genannt werden. Bei den Patientinnen mit HER2−/HR+-Mammakarzinom sind insbesondere die CDK4/6-Inhibitoren und der PIK3CA-Inhibitor Alpelisib zu nennen. Weitere, neue Therapien wie Akt-Kinase-Inhibitoren und orale SERDs (selective estrogen receptor down-regulators) werden bereits in laufenden klinischen Studien untersucht. Nicht nur bei den HER2-positiven Tumoren halten die Therapien Einzug in die kurative, (neo-) adjuvante Therapiesituation, sondern es wurde nun eine erste positive Studie mit Abemaciclib in der adjuvanten Situation vorgestellt. Bei Patientinnen mit einem triple-negativen Mammakarzinom ist nach vielen Jahren mit negativen Studienergebnissen mit dem Trop-2-Antikörper-Wirkstoff-Konjugat (antibody drug conjugate, ADC) Sacituzumab-Govitecan eine randomisierte Studie veröffentlicht worden, die einen deutlichen Therapiefortschritt bedeuten kann. Diese Übersichtsarbeit beschreibt die neuesten Entwicklungen beim Mammakarzinom nach dem ESMO-Kongress 2020.

show abstract

275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

Cited by 6 publications

References 0 publications

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Update Mammakarzinom 2020 Teil 5 – Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation

Contact Info

Product

Resources

About